CY1113930T1 - Ενωσεις χρησιμες στην αναστολη της chk1 - Google Patents

Ενωσεις χρησιμες στην αναστολη της chk1

Info

Publication number
CY1113930T1
CY1113930T1 CY20131100305T CY131100305T CY1113930T1 CY 1113930 T1 CY1113930 T1 CY 1113930T1 CY 20131100305 T CY20131100305 T CY 20131100305T CY 131100305 T CY131100305 T CY 131100305T CY 1113930 T1 CY1113930 T1 CY 1113930T1
Authority
CY
Cyprus
Prior art keywords
useful
chk1
unions
suspension
solvate
Prior art date
Application number
CY20131100305T
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Coatsworth Holcomb
Ramesh Kasar
Steven Scott Myers
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113930T1 publication Critical patent/CY1113930T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Η παρούσα εφεύρεση παρέχει μία ένωση αμινοπυραζόλης, ή φαρμακευτικώς αποδεκτό άλας αυτής ή επιδιαλυτωμένο άλας αυτής, που αναστέλλει την Chk1 και χρησιμεύει στην αγωγή έναντι του καρκίνου.
CY20131100305T 2008-12-17 2013-04-11 Ενωσεις χρησιμες στην αναστολη της chk1 CY1113930T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17
EP09768586A EP2379532B1 (en) 2008-12-17 2009-12-10 Compounds useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
CY1113930T1 true CY1113930T1 (el) 2016-07-27

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100305T CY1113930T1 (el) 2008-12-17 2013-04-11 Ενωσεις χρησιμες στην αναστολη της chk1

Country Status (38)

Country Link
EP (1) EP2379532B1 (el)
JP (1) JP5705743B2 (el)
KR (1) KR101301777B1 (el)
CN (1) CN102245597B (el)
AR (1) AR074471A1 (el)
AU (1) AU2009333433B2 (el)
BR (1) BRPI0922468A2 (el)
CA (1) CA2746423C (el)
CL (1) CL2011001463A1 (el)
CO (1) CO6382122A2 (el)
CR (1) CR20110339A (el)
CY (1) CY1113930T1 (el)
DK (1) DK2379532T3 (el)
DO (1) DOP2011000185A (el)
EA (1) EA018118B1 (el)
EC (1) ECSP11011136A (el)
ES (1) ES2401558T3 (el)
HK (1) HK1160110A1 (el)
HN (1) HN2011001446A (el)
HR (1) HRP20130167T1 (el)
IL (1) IL213160A (el)
JO (1) JO2886B1 (el)
MA (1) MA32901B1 (el)
MX (1) MX2011006603A (el)
MY (1) MY156998A (el)
NZ (1) NZ593440A (el)
PA (1) PA8850801A1 (el)
PE (1) PE20120077A1 (el)
PL (1) PL2379532T3 (el)
PT (1) PT2379532E (el)
RS (1) RS52739B (el)
SG (1) SG172222A1 (el)
SI (1) SI2379532T1 (el)
TN (1) TN2011000298A1 (el)
TW (1) TWI436996B (el)
UA (1) UA101998C2 (el)
WO (1) WO2010077758A1 (el)
ZA (1) ZA201103946B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
AR083575A1 (es) * 2010-11-08 2013-03-06 Lilly Co Eli Aminopirazoles para inhibir la proteinquinasa chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
AR106772A1 (es) * 2015-12-07 2018-02-14 Lilly Co Eli Sales de (s)-lactato
SG11201803903YA (en) * 2015-12-15 2018-06-28 Lilly Co Eli Combination therapy for cancer
EP3411036B1 (en) * 2016-02-04 2021-12-29 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
MX2019011506A (es) 2017-03-31 2019-11-01 Seattle Genetics Inc Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN114746413B (zh) * 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
CN116546974A (zh) * 2020-11-30 2023-08-04 住友制药株式会社 5-杂芳基-1h-吡唑-3-胺衍生物
KR20240021188A (ko) 2021-05-27 2024-02-16 바운드리스 바이오, 인크. 체크포인트 키나제 1(chk1) 억제제 및 그의 용도
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
TW202333680A (zh) * 2021-12-24 2023-09-01 日商住友製藥股份有限公司 具有二環性骨架之1h-吡唑-3-胺衍生物
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
JP2006528661A (ja) * 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
DK2379532T3 (da) 2013-03-18
AU2009333433B2 (en) 2012-06-14
EA201170834A1 (ru) 2011-12-30
ES2401558T3 (es) 2013-04-22
KR20110084539A (ko) 2011-07-25
HN2011001446A (es) 2013-08-05
ECSP11011136A (es) 2011-07-29
EA018118B1 (ru) 2013-05-30
PA8850801A1 (es) 2010-07-27
AR074471A1 (es) 2011-01-19
WO2010077758A1 (en) 2010-07-08
CN102245597B (zh) 2014-04-16
KR101301777B1 (ko) 2013-08-30
EP2379532A1 (en) 2011-10-26
MY156998A (en) 2016-04-15
MA32901B1 (fr) 2011-12-01
CA2746423A1 (en) 2010-07-08
TWI436996B (zh) 2014-05-11
IL213160A (en) 2013-12-31
CL2011001463A1 (es) 2012-01-20
JO2886B1 (en) 2015-03-15
PT2379532E (pt) 2013-03-25
BRPI0922468A2 (pt) 2020-08-04
CR20110339A (es) 2011-09-14
EP2379532B1 (en) 2013-02-20
DOP2011000185A (es) 2017-12-15
HRP20130167T1 (hr) 2013-03-31
PL2379532T3 (pl) 2013-07-31
RS52739B (en) 2013-08-30
PE20120077A1 (es) 2012-02-06
SG172222A1 (en) 2011-07-28
TW201029994A (en) 2010-08-16
MX2011006603A (es) 2011-09-27
ZA201103946B (en) 2012-10-31
CO6382122A2 (es) 2012-02-15
IL213160A0 (en) 2011-07-31
SI2379532T1 (sl) 2013-05-31
CA2746423C (en) 2014-01-14
AU2009333433A1 (en) 2011-06-30
JP5705743B2 (ja) 2015-04-22
CN102245597A (zh) 2011-11-16
UA101998C2 (ru) 2013-05-27
HK1160110A1 (en) 2012-08-10
JP2012512249A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
CY1113930T1 (el) Ενωσεις χρησιμες στην αναστολη της chk1
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1119199T1 (el) Αναστολεις cdc7
CY1120135T1 (el) Αναστολεις κινασης τυροσινης bruton
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
EA201171367A1 (ru) Винилиндазолильные соединения
CY1124331T1 (el) Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
CY1114608T1 (el) Θεραπειες συνδυασμου που περιλαμβανουν κινοξαλινη αναστολεα pι3k αλφα για χρηση στην θεραπεια του καρκινου
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CY1121334T1 (el) Αναστολεας κινασης aurora a
CY1119432T1 (el) Αναστολεiς πυραζολυλ-γουανιδινο-f1f0-ατρασης και θεραπευτικες χρησεις αυτωn
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
CY1116362T1 (el) Ενωσεις χρησιμες στην αναστολη της chk1
CY1114609T1 (el) Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
CY1115576T1 (el) Αναστολεις jακ2 και χρηση αυτων για τη θεραπεια μυελοπολλαπλασιαστικων ασθενειων και καρκινου